Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 7;28(10):2110–2117. doi: 10.1158/1078-0432.CCR-22-0041

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©2022 The Authors; Published by the American Association for Cancer Research

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

PMC Copyright notice

Figure 3. Kaplan–Meier plots of progression-free survival (PFS; A) and overall survival (OS; B) according to the expression of VEGF-A mRNA. Patients with high VEGF-A mRNA expression, compared with those with low expression, had significantly lower PFS [median: 4.8 months; (95% CI, 3.0–30.7) vs. not reached, NR (95% CI, 8.4–NR), log-rank P = 0.025] and OS [median, 11.1 months; (95% CI, 5.3–NR) vs. NR (95% CI, 15.2 to NR); log-rank P = 0.035]. — Kaplan–Meier plots of progression-free survival (PFS; A) and overall survival (OS; B) according to the expression of VEGF-A mRNA. Patients with high VEGF-A mRNA expression, compared with those with low expression, had significantly lower PFS [median: 4.8 months; (95% CI, 3.0–30.7) vs. not reached, NR (95% CI, 8.4–NR); log-rank P = 0.025] and OS [median, 11.1 months; (95% CI, 5.3–NR) vs. NR (95% CI, 15.2–NR); log-rank P = 0.035].